Skyrizi® On-Body Injector for Crohn's Disease and Ulcerative Colitis

This medicine is a prescription biologic for immune-mediated disease. The wearable injector supports at-home maintenance for adults with Crohn’s disease and ulcerative colitis. This page explains how it works, who it suits, and how to request access without insurance.

What Skyrizi Is and How It Works

This page supports US shipping from Canada for the wearable maintenance injector. CanadianInsulin.com is a prescription referral platform. We verify prescriptions with your prescriber when required, and licensed Canadian pharmacies dispense your order.

Skyrizi® contains risankizumab-rzaa, a humanized monoclonal antibody that selectively targets the p19 subunit of interleukin‑23. By reducing IL‑23 signaling, it can decrease inflammatory activity in the gut and skin. The therapy is indicated for adults with moderate to severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This presentation includes a medication cartridge that attaches to a wearable injector for hands‑free administration during the maintenance phase after IV induction. The Skyrizi Pre-fill Cartridge w/ Injector is designed for clinician‑directed maintenance treatment in Crohn’s disease and ulcerative colitis.

Who It’s For

This treatment is for adults with moderate to severe Crohn’s disease or ulcerative colitis who have completed the approved IV induction phase and are moving to subcutaneous maintenance. Adults with plaque psoriasis or psoriatic arthritis also use this medicine, but those conditions typically use prefilled syringes or pens rather than the wearable maintenance device. People with a history of serious or chronic infections, or who are currently ill, should discuss risks with a healthcare professional.

Screen for tuberculosis before starting. Avoid live vaccines during therapy. Those with known hypersensitivity to risankizumab should not use it. For condition-specific information, see Crohn’s Disease, Ulcerative Colitis, and Psoriasis. For platform availability details, you can review Skyrizi cartridge with injector online information on this page.

Dosage and Usage

Maintenance dosing begins after the labeled IV induction course prescribed by your clinician. The wearable system is applied to intact skin as directed and delivers the dose automatically. The Risankizumab 360 mg on-body injector reference describes the maintenance strength used after induction for Crohn’s disease and ulcerative colitis per labeling. Subsequent doses are administered on a regular interval schedule set by your prescriber, often every eight weeks.

General steps include preparing supplies, letting the device reach room temperature out of the refrigerator, cleaning the injection site, attaching the device as directed, starting the injection, and confirming completion by indicator status. Rotate sites on the abdomen or thigh. Do not inject into tender, bruised, or scarred areas. Read and follow the Instructions for Use included with the product. If uncertain, defer to the official label or speak with a healthcare professional.

Strengths and Forms

Availability may vary by dispensing pharmacy. Common presentations include:

• Risankizumab-rzaa 360 mg cartridge used with an on-body wearable device for GI maintenance after IV induction.
• Prefilled syringes and pens for skin and joint indications, typically administered at different intervals than the wearable device.

Missed Dose and Timing

If you miss a planned maintenance dose, take it as soon as you can. Then follow the regular schedule from the new date, unless your clinician provides other instructions. If the device fails to complete the injection or you are unsure whether the full dose was delivered, consult the Instructions for Use and contact your healthcare professional for guidance.

Storage and Travel Basics

Store in a refrigerator at 2 to 8°C in the original carton to protect from light. Do not freeze. Do not shake. When ready, allow the device and cartridge to reach room temperature naturally. Keep away from heat sources. For travel, place the product in an insulated container with cool packs, protecting it from freezing and direct sunlight. Carry it in hand luggage with documentation of your prescription. Follow airline and security requirements. A micro-cue for safety: encrypted checkout and temperature-controlled handling when required.

Pen Handling and Sharps Disposal

This is a single-use wearable injector and a matching cartridge. Use each cartridge and device only once. Do not modify, reuse, or share. After use, place the empty device and any sharps in an FDA-cleared sharps container. If none is available, use a heavy-duty puncture-resistant household container with a tight-fitting lid and follow local disposal rules. Keep all components out of reach of children and pets.

Benefits

This maintenance approach allows at-home dosing after IV induction. The wearable delivery can simplify administration by automating the injection once placed correctly on the skin. Extended intervals between doses may reduce appointment burden and help support adherence. Many patients appreciate not handling a syringe, since the device controls the injection once activated. As with all biologics, individual response varies, and the overall plan should be managed by your clinician.

Side Effects and Safety

• Injection site redness, pain, or swelling
• Headache or fatigue
• Upper respiratory symptoms such as sore throat or cough
• Stomach discomfort or nausea
• Rash or itching

Serious risks can include infections that may become severe, hypersensitivity reactions, and rare events noted in the label. Tell your clinician about fevers, persistent cough, weight loss, night sweats, or any signs of infection. Hold therapy and seek medical attention if you suspect a severe allergic reaction. Avoid live vaccines during treatment.

Drug Interactions and Cautions

Live vaccines should be avoided during therapy and for a period before/after as directed by the label. Other immunomodulators may increase infection risk. Discuss all prescription medicines, over-the-counter drugs, and herbal supplements with your prescriber. Screening for tuberculosis and evaluation for chronic infections or hepatitis risk are recommended before starting. If you develop a serious infection, contact your healthcare professional promptly.

What to Expect Over Time

This maintenance therapy is intended to help sustain response after the induction phase. Some symptoms may diminish gradually, while other changes can take longer. Keep routine follow-up with your healthcare professional to monitor disease activity and safety. Using the device on schedule, rotating sites, and storing it correctly can support consistent dosing. Report persistent or worsening symptoms, infections, or any device problems.

Compare With Alternatives

Other biologic options for similar conditions include ustekinumab and adalimumab. Ustekinumab is available as a prefilled syringe and has IV induction plus subcutaneous maintenance in GI disease. See Stelara Pre Filled Syringe. Adalimumab is a subcutaneous TNF inhibitor used across multiple immune conditions; see Humira. For broader clinical context, you may also read our article on comparative safety signals: Ustekinumab vs Adalimumab.

Pricing and Access

We display transparent Skyrizi Canadian pricing for the wearable maintenance presentation when available. Personal costs vary by dose, supply, and the dispensing pharmacy. Pricing may differ for self-pay versus insurance claims. This platform supports US delivery from Canada with a secure checkout flow. If you are looking for current deals, visit our Promotions page. Final costs are shown before you confirm.

Availability and Substitutions

Stock can vary. If this presentation is unavailable, a prescriber may recommend an alternative format or a different approved biologic based on your condition and treatment history. We cannot provide restock dates. Your clinician determines whether a substitution is appropriate.

Patient Suitability and Cost-Saving Tips

Good candidates have completed the labeled induction course and need ongoing maintenance under clinician supervision. Those with active, clinically important infections or uncontrolled chronic infections may not be suitable. Discuss screening, vaccination plans, and pregnancy considerations with your prescriber.

To help manage the Skyrizi out of pocket cost, consider multi‑month fills if your prescriber approves, which may reduce per‑fill fees. Set reminders for refill timing so you do not miss maintenance windows. Align deliveries with travel to keep doses on schedule. Save receipts and explanation‑of‑benefits statements for reimbursement review as applicable.

Questions to Ask Your Clinician

• Induction complete plan: confirm maintenance timing
• Device training: who teaches first use
• Injection sites: best locations for you
• Monitoring: what labs or visits are needed
• Vaccines: which to avoid and when
• Infections: what symptoms to report
• Travel: storage plans and documentation

Authoritative Sources

• Skyrizi Prescribing Information (AbbVie)
• FDA DailyMed: Risankizumab-rzaa
• Health Canada Drug Product Database

Ready to proceed? Place your request with prompt, cold-chain shipping and US shipping from Canada. This page is informational and not a substitute for medical advice; always follow your prescriber and the official label.